EE200000658A - CD23 antikehad, nende derivaadid ja nende terapeutiline kasutamine - Google Patents

CD23 antikehad, nende derivaadid ja nende terapeutiline kasutamine

Info

Publication number
EE200000658A
EE200000658A EEP200000658A EEP200000658A EE200000658A EE 200000658 A EE200000658 A EE 200000658A EE P200000658 A EEP200000658 A EE P200000658A EE P200000658 A EEP200000658 A EE P200000658A EE 200000658 A EE200000658 A EE 200000658A
Authority
EE
Estonia
Prior art keywords
antibodies
derivatives
therapeutic use
therapeutic
Prior art date
Application number
EEP200000658A
Other languages
English (en)
Estonian (et)
Inventor
Marcel Paul Bonnefoy Jean-Yves
James Crowe Scott
Henry Ellis Jonathan
Timothy Rapson Nicholas
Shearin Jean
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of EE200000658A publication Critical patent/EE200000658A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EEP200000658A 1998-05-09 1999-05-07 CD23 antikehad, nende derivaadid ja nende terapeutiline kasutamine EE200000658A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9809839.5A GB9809839D0 (en) 1998-05-09 1998-05-09 Antibody
PCT/GB1999/001434 WO1999058679A1 (en) 1998-05-09 1999-05-07 Antibodies to cd23, derivatives thereof, and their therapeutic uses

Publications (1)

Publication Number Publication Date
EE200000658A true EE200000658A (et) 2002-04-15

Family

ID=10831668

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200000658A EE200000658A (et) 1998-05-09 1999-05-07 CD23 antikehad, nende derivaadid ja nende terapeutiline kasutamine

Country Status (25)

Country Link
US (1) US7008623B1 (no)
EP (1) EP1076701A1 (no)
JP (1) JP2002514421A (no)
KR (1) KR20010043470A (no)
CN (1) CN1308676A (no)
AP (1) AP1547A (no)
AU (1) AU763491B2 (no)
BR (1) BR9910327A (no)
CA (1) CA2328606A1 (no)
EA (1) EA200001041A1 (no)
EE (1) EE200000658A (no)
GB (1) GB9809839D0 (no)
HR (1) HRP20000762A2 (no)
HU (1) HUP0102005A3 (no)
ID (1) ID28088A (no)
IL (1) IL139384A0 (no)
IS (1) IS5696A (no)
NO (1) NO20005632L (no)
NZ (1) NZ507879A (no)
PL (1) PL344019A1 (no)
SK (1) SK16762000A3 (no)
TR (1) TR200003281T2 (no)
WO (1) WO1999058679A1 (no)
YU (1) YU69000A (no)
ZA (1) ZA200006312B (no)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696550B2 (en) 1998-07-23 2004-02-24 Millennium Pharmaceuticals, Inc. Humanized anti-CCR2 antibodies and methods of use therefor
MXPA03003144A (es) 2000-10-13 2004-12-06 Biogen Inc Anticuerpos humanizados anti-lt-??-r.
US20040151721A1 (en) 2001-10-19 2004-08-05 O'keefe Theresa Humanized anti-CCR2 antibodies and methods of use therefor
CN1678625A (zh) * 2002-07-01 2005-10-05 比奥根艾迪克Ma公司 人源化抗淋巴毒素β受体的抗体
TWI323265B (en) 2002-08-06 2010-04-11 Glaxo Group Ltd Antibodies
GB0306309D0 (en) 2003-03-19 2003-04-23 Glaxo Group Ltd Method of treatment
CA2529945A1 (en) 2003-06-27 2005-01-06 Biogen Idec Ma Inc. Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
CA2434668A1 (en) 2003-07-04 2005-01-04 Laurence Mulard Novel approach to design glycopeptides based on o-specific polysaccharide of shigella flexneri serotype 2a
AU2003300896A1 (en) * 2003-12-10 2005-07-14 Millennium Pharmaceuticals, Inc. Humanized anti-ccr2 antibodies and methods of use
US7435799B2 (en) * 2004-01-08 2008-10-14 Applied Molecular Evolution TNF-α binding molecules
AU2005227322A1 (en) 2004-03-23 2005-10-06 Biogen Idec Ma Inc. Receptor coupling agents and therapeutic uses thereof
US20060246075A1 (en) * 2004-09-29 2006-11-02 Marc Mercken Anti-amyloid antibodies, compositions, methods and uses
WO2006074399A2 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
MY153249A (en) 2005-11-14 2015-01-29 Rinat Neuroscience Corp Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
GB0525662D0 (en) 2005-12-16 2006-01-25 Glaxo Group Ltd Immunoglobulins
EP1804172B1 (en) * 2005-12-20 2021-08-11 Roche Diagnostics GmbH PCR elbow determination using curvature analysis of a double sigmoid
US7680868B2 (en) * 2005-12-20 2010-03-16 Roche Molecular Systems, Inc. PCR elbow determination by use of a double sigmoid function curve fit with the Levenburg-Marquardt algorithm and normalization
WO2009043051A2 (en) * 2007-09-27 2009-04-02 Biogen Idec Ma Inc. Cd23 binding molecules and methods of use thereof
AU2008328726B2 (en) 2007-11-30 2014-06-12 Glaxo Group Limited Antigen-binding constructs
CA2716424C (en) 2008-03-04 2015-04-28 Pfizer Limited Methods of treating chronic pain
PE20091829A1 (es) 2008-05-06 2009-12-12 Glaxo Group Ltd Encapsulacion de agentes biologicamente activos
JP2012518398A (ja) 2009-02-24 2012-08-16 グラクソ グループ リミテッド 抗原結合性構築物
US20110305694A1 (en) 2009-02-24 2011-12-15 Paul Andrew Hamblin Multivalent and/or multispecific rankl-binding constructs
WO2010097386A1 (en) 2009-02-24 2010-09-02 Glaxo Group Limited Antigen-binding constructs
CA2757237A1 (en) 2009-04-01 2010-10-14 Jane Elizabeth Clarkson Anti-il-23 immunoglobulins
CA2758842A1 (en) 2009-04-24 2010-10-28 Glaxo Group Limited Fgfr1c antibody combinations
KR101519192B1 (ko) 2009-08-28 2015-05-11 리나트 뉴로사이언스 코프. 칼시토닌 유전자-관련된 펩티드에 대해 지시된 길항제 항체의 투여에 의한 내장 통증의 치료 방법
FR2957598B1 (fr) * 2010-03-17 2015-12-04 Lfb Biotechnologies Nouveau peptide signal, et son utilisation pour la production de proteines recombinantes
AR083937A1 (es) 2010-11-23 2013-04-10 Glaxo Group Ltd Proteinas de union a antigenos
US20130236467A1 (en) 2010-11-24 2013-09-12 Jeremy Griggs Multispecific antigen binding proteins targeting hgf
US8974782B2 (en) 2011-02-07 2015-03-10 Glaxo Group Limited Treatment of stroke comprising anti-MAG antibodies
CA2833820C (en) 2011-05-27 2019-10-29 Glaxo Group Limited Bcma (cd269/tnfrsf17) -binding proteins
WO2014029752A1 (en) 2012-08-22 2014-02-27 Glaxo Group Limited Anti lrp6 antibodies
US10176293B2 (en) 2012-10-02 2019-01-08 Roche Molecular Systems, Inc. Universal method to determine real-time PCR cycle threshold values
EA037554B1 (ru) 2013-03-15 2021-04-13 Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Анти-lag-3 связывающие белки
JP6440036B2 (ja) * 2013-07-10 2018-12-19 オンコノックス エーピーエス 抗β２−グリコプロテインＩ抗体及びその治療的用法
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
PE20161439A1 (es) 2014-03-21 2017-01-26 Teva Pharmaceuticals Int Gmbh Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos
KR20250073532A (ko) 2015-09-02 2025-05-27 이뮤텝 에스.에이.에스. 항-lag-3 항체
US10479827B2 (en) * 2016-05-31 2019-11-19 Sysmex Corporation Monoclonal antibody reacting with glycopeptide, and use thereof
JP6935184B2 (ja) * 2016-05-31 2021-09-15 シスメックス株式会社 糖ペプチドと反応するモノクローナル抗体およびその用途
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
WO2018055574A1 (en) 2016-09-23 2018-03-29 Teva Pharmaceuticals International Gmbh Treating refractory migraine
CN111629715A (zh) 2018-01-18 2020-09-04 弗莱德哈钦森癌症研究中心 通过调节细胞活化状态改变体内免疫细胞的炎症状态
PE20220568A1 (es) 2019-05-21 2022-04-20 Novartis Ag Moleculas de union a cd19 y usos de las mismas
KR20220026585A (ko) 2019-06-26 2022-03-04 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Il1rap 결합 단백질
CN112552403A (zh) * 2020-12-25 2021-03-26 南京英瀚斯生物科技有限公司 一种人源抗人CD23抗体的Fab片段、药物组合物及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE922437A1 (en) * 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
CA2114015C (en) * 1991-07-25 2002-12-10 Roland A. Newman Recombinant antibodies for human therapy
DK0788513T3 (da) * 1994-10-25 2001-04-02 Glaxo Group Ltd Anvendelse af bindingsmidler for CD23 i behandlingen af atoimmune sygdomme
US6011138A (en) 1997-02-20 2000-01-04 Idec Pharmaceuticals Corporation Gamma-1 anti-human CD23 monoclonal antibodies

Also Published As

Publication number Publication date
TR200003281T2 (tr) 2001-03-21
CA2328606A1 (en) 1999-11-18
IS5696A (is) 2000-10-31
NO20005632D0 (no) 2000-11-08
PL344019A1 (en) 2001-09-24
ZA200006312B (en) 2003-02-26
BR9910327A (pt) 2001-01-30
NZ507879A (en) 2004-02-27
WO1999058679A1 (en) 1999-11-18
EA200001041A1 (ru) 2001-06-25
HUP0102005A3 (en) 2003-10-28
HUP0102005A2 (hu) 2001-10-28
SK16762000A3 (sk) 2001-07-10
AU763491B2 (en) 2003-07-24
NO20005632L (no) 2001-01-08
JP2002514421A (ja) 2002-05-21
ID28088A (id) 2001-05-03
HRP20000762A2 (en) 2001-06-30
US7008623B1 (en) 2006-03-07
AP1547A (en) 2006-01-13
IL139384A0 (en) 2001-11-25
YU69000A (sh) 2003-08-29
EP1076701A1 (en) 2001-02-21
AU3836799A (en) 1999-11-29
CN1308676A (zh) 2001-08-15
KR20010043470A (ko) 2001-05-25
AP2000001983A0 (en) 2000-12-31
GB9809839D0 (en) 1998-07-08

Similar Documents

Publication Publication Date Title
EE200000658A (et) CD23 antikehad, nende derivaadid ja nende terapeutiline kasutamine
EE200200251A (et) Uued N-asabitsükloamiidi derivaadid ja nende kasutamine
FI955235A7 (fi) Oksatsolidiinionijohdannaiset, niiden valmistus ja käyttö
EE200200175A (et) Asendatud 2-tio-3,5-ditsüano-4-arüül-6-aminopüridiinid ja nende kasutamine
EE04565B1 (et) Adamantaani derivaadid, nende saamine ja kasutamine
IS2277B (is) Meðferðarlegar bíarýl afleiður
NO20021379D0 (no) Benzodiazepin-derivater, fremstilling og anvendelse derav
DK0869126T3 (da) Dithiolanderivater, deres fremstilling og deres terapeutiske virkning
EE200100185A (et) Asendatud fenüülderivaadid, nende valmistamine jakasutamine
EE04721B1 (et) Fenüülksantiini derivaadid, nende valmistamismeetodid ja kasutamine
EE200000621A (et) Pikornaviirusevastased ühendid, nende valmistamine ja kasutamine
EE200100470A (et) Püridopüranoasepiini derivaadid, nende valmistamine ja terapeutiline kasutamine
EE200300311A (et) Ftalasinoon-piperidinoderivaadid, nende kasutamine ja ravim
EE04151B1 (et) Atsüülpiperasinüülpürimidiinide derivaadid, nendevalmistamine ja kasutamine ravimitena
FI956298A0 (fi) 3-fenyyli-isokinolin-1(2H)-oneja, niiden valmistus ja terapeuttinen käyttö
FI970997A7 (fi) Bentsosykloalkeeniyhdisteet, niiden valmistus ja käyttö
DK1025100T3 (da) 3-substituerede tetrahydropyridopyrimidinonderivater, fremstilling og anvendelsen heraf
FI970750L (fi) Indoli-2,3-dioni-3-oksimijohdannaisia, niiden valmistus ja käyttö
EE200000018A (et) 6-pürrolidiin-2-üülpüridiinid, nende valmistamine ja terapeutiline kasutamine
FI971317A7 (fi) Uusia heterosyklisiä, substituoituja imidatsolokinoksalinoneja, niiden valmistus ja käyttö
FI965172L (fi) Uusia amido-kinoksaliinidioneja, niiden valmistus ja käyttö
EE9800153A (et) 5-naftalen-1-üül-1,3-dioksaani derivaadid, nende valmistamine ja terapeutiline kasutamine
EE9900560A (et) 5-naftaleen-1-üül-1,3-dioksaani derivaadid, nende valmistamine ja terapeutiline kasutamine
FI950021A7 (fi) Tienopyrimidiinijohdannaiset, niiden valmistus ja käyttö
FI945314L (fi) Tetrasolijohdannaiset, niiden valmistus ja käyttö